Navigation Links
Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
Date:2/27/2012

SAN DIEGO, Feb. 27, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 32nd Annual Cowen Health Care Conference on Wednesday, March 7 at 8:40 AM Eastern Time in Boston, MA.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of the presentation will be available at the same location for 90 days following the presentation.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736
Dwalsey@optimerpharma.com

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005
Jason@canalecomm.com

 

 

 


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
2. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
5. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
6. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
7. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
8. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
9. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
11. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... MARLBOROUGH, Mass. , March 22, 2017 ... that it has completed the acquisition of Cynosure, Inc., ... $66 per share in cash. "We are ... forward to working with Michael Davin and ... in the large, rapidly growing medical aesthetics market," said ...
(Date:3/22/2017)... NEW YORK , March 22, 2017 ... Electrophysiology (EP) market is growing rapidly due to the ... a report published by Allied Market Research, the global ... is expected to reach $8.271 billion by 2022, with ... cardiology and is used to diagnose abnormal heartbeats or ...
(Date:3/22/2017)... March 22, 2017  As the world,s leading non-profit ... Society (LLS) has played a role in most therapies ... which are even helping patients with other cancers and ... significant investment in cutting-edge research – more than $1 ... grow with the record-breaking sum of $4.1 million raised ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... News Advisory/Interview Opportunity , After ... score a major victory in Europe for public health and the environment and is ... on rigorous scientific research and the overwhelming support of European citizens, the European Union ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response ... Respectful Response To Atheist Manifesto” is the creation of published author Richard Hostetter, ... for sixty years. He holds graduate degrees from Kent State University and the ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... the publication of the first issue of its companion print magazine. The new ... about cosmetic surgery thanks to information provided by board-certified doctors from across the ...
(Date:3/22/2017)... ... ... Old School Labs™, makers of the best-selling Vintage line of natural sports ... who trained with Floyd Mayweather, made his professional debut in London in 2003 and ... number of wins in contests in Britain, Germany and the U.S. , “We ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... solution provider, today announced that its digital marketing solutions have enabled Children’s Hospital ... investment in 24 months. , Recognizing the value of a digital marketing ...
Breaking Medicine News(10 mins):